

# Resistance to second-line injectables and treatment outcomes in extensively drug-resistant tuberculosis cases

European Respiratory Journal

31, 1155-1159

DOI: [10.1183/09031936.00028708](https://doi.org/10.1183/09031936.00028708)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The Emergence of Extensively Drug-Resistant Tuberculosis: A Global Health Crisis Requiring New Interventions: Part I: The Origins and Nature of the Problem. <i>Clinical and Translational Science</i> , 2008, 1, 249-254.	3.1	8
2	Extensively drug-resistant tuberculosis: new strains, new challenges. <i>Expert Review of Anti-Infective Therapy</i> , 2008, 6, 713-724.	4.4	37
3	Extensively drug-resistant tuberculosis: is its definition correct?. <i>European Respiratory Journal</i> , 2008, 32, 1413-1415.	6.7	13
4	Update on clinical research of tuberculosis: a report from the European Respiratory Society. <i>Expert Review of Respiratory Medicine</i> , 2008, 2, 707-711.	2.5	0
5	Extensively Drug-Resistant Tuberculosis in the United States, 1993-2007. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 2153.	7.4	104
6	Of Blind Men and Elephants: Making Sense of Extensively Drug-resistant Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 1000-1001.	5.6	16
7	Multidrug- and Extensively Drug-Resistant Tuberculosis, Germany. <i>Emerging Infectious Diseases</i> , 2008, 14, 1700-1706.	4.3	113
8	Multidrug-resistant and extensively drug-resistant tuberculosis: a review. <i>Current Opinion in Infectious Diseases</i> , 2008, 21, 587-595.	3.1	136
9	Extensively Drug-resistant Tuberculosis(XDR-TB). <i>Journal of Medicine (Bangladesh)</i> , 2009, 10, 97-99.	0.2	0
10	Disseminated multiorgan MDR-TB resistant to virtually all first-line drugs. <i>European Respiratory Review</i> , 2009, 18, 291-294.	7.1	3
11	Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. <i>European Respiratory Journal</i> , 2009, 33, 1085-1094.	6.7	116
12	A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2009, 34, 387-393.	6.7	170
13	Extensively drug-resistant tuberculosis in the UK: 1995 to 2007. <i>Thorax</i> , 2009, 64, 512-515.	5.6	22
14	Multidrug-Resistant Tuberculosis (TB) Resistant to Fluoroquinolones and Streptomycin but Susceptible to Second-Line Injection Therapy Has a Better Prognosis than Extensively Drug-Resistant TB. <i>Clinical Infectious Diseases</i> , 2009, 48, e50-e52.	5.8	28
15	Multidrug- and extensively drug-resistant TB in persons living with HIV. <i>Expert Review of Respiratory Medicine</i> , 2009, 3, 245-254.	2.5	8
16	From the authors:. <i>European Respiratory Journal</i> , 2009, 34, 780-781.	6.7	0
17	Update in Tuberculosis 2008. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 337-343.	5.6	4
18	Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB. <i>European Respiratory Journal</i> , 2009, 33, 581-585.	6.7	28

#	ARTICLE	IF	CITATIONS
19	Multidrug- and extensively drug-resistant tuberculosis: an emerging threat. <i>European Respiratory Review</i> , 2009, 18, 195-197.	7.1	27
20	To the Editors:. <i>European Respiratory Journal</i> , 2009, 34, 780-780.	6.7	0
21	Steps forward in LRTI and tuberculosis: update from the ERS Respiratory Infections Assembly. <i>European Respiratory Journal</i> , 2009, 33, 1448-1453.	6.7	2
22	MDR-TB and XDR-TB: drug resistance and treatment outcomes. <i>European Respiratory Journal</i> , 2009, 34, 778-779.	6.7	30
23	Consensus Not Yet Reached on Key Drugs for Extensively Drug-Resistant Tuberculosis Treatment. <i>Clinical Infectious Diseases</i> , 2009, 49, 315-316.	5.8	6
24	High-throughput screening for inhibitors of <i>Mycobacterium tuberculosis</i> H37Rv. <i>Tuberculosis</i> , 2009, 89, 334-353.	1.9	251
25	Investigations into Viomycin Biosynthesis by Using Heterologous Production in <i>Streptomyces lividans</i> . <i>ChemBioChem</i> , 2009, 10, 366-376.	2.6	47
26	Treatment Outcomes of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2009, 4, e6914.	2.5	346
27	Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in the West. Europe and United States: Epidemiology, Surveillance, and Control. <i>Clinics in Chest Medicine</i> , 2009, 30, 637-665.	2.1	64
28	Multidrug- and Extensively Drug-resistant Tuberculosis in Africa and South America: Epidemiology, Diagnosis and Management in Adults and Children. <i>Clinics in Chest Medicine</i> , 2009, 30, 667-683.	2.1	50
29	Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. <i>European Respiratory Journal</i> , 2009, 33, 871-881.	6.7	163
31	Extensively drug-resistant tuberculosis. <i>Current Opinion in Infectious Diseases</i> , 2009, 22, 167-173.	3.1	65
32	Emerging epidemic of drug-resistant tuberculosis in Europe, Russia, China, South America and Asia: current status and global perspectives. <i>Current Opinion in Pulmonary Medicine</i> , 2010, 16, 1.	2.6	18
33	Drug-resistant tuberculosis: Past, present, future. <i>Respirology</i> , 2010, 15, 413-432.	2.3	110
34	The making of the ERJ: behind the scenes and Editors' cut. <i>European Respiratory Journal</i> , 2010, 36, 4-5.	6.7	8
35	Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004. <i>European Respiratory Journal</i> , 2010, 36, 584-593.	6.7	72
36	Factors Associated with Multidrug-resistant Tuberculosis: Comparison of Patients Born inside and outside of the Czech Republic. <i>Journal of International Medical Research</i> , 2010, 38, 1156-1163.	1.0	7
37	Development of a standardised tool to survey MDR-/XDR-TB case management in Europe. <i>European Respiratory Journal</i> , 2010, 36, 208-211.	6.7	22

#	ARTICLE	IF	CITATIONS
38	Impact of Extensively Drug-Resistant Tuberculosis on Treatment Outcome of Multidrug-Resistant Tuberculosis Patients with Standardized Regimen: Report from Iran. <i>Microbial Drug Resistance</i> , 2010, 16, 81-86.	2.0	22
39	Clinical Pharmacology and Lesion Penetrating Properties of Second- and Third-Line Antituberculous Agents Used in the Management of Multidrug-Resistant (MDR) and Extensively-Drug Resistant (XDR) Tuberculosis. <i>Current Clinical Pharmacology</i> , 2010, 5, 96-114.	0.6	39
40	Treatment Outcomes and Survival Based on Drug Resistance Patterns in Multidrug-resistant Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 113-119.	5.6	110
41	Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. <i>Lancet, The</i> , 2010, 375, 1798-1807.	13.7	225
42	Tuberculosis and air travel: a systematic review and analysis of policy. <i>Lancet Infectious Diseases, The</i> , 2010, 10, 176-183.	9.1	49
43	Molecular Characterization of Fluoroquinolone Resistance in <i>Mycobacterium tuberculosis</i> : Functional Analysis of <i>gyrA</i> Mutation at Position 74. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 608-614.	3.2	57
44	WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. <i>European Respiratory Journal</i> , 2011, 38, 516-528.	6.7	718
45	Outcome of hospitalized MDR-TB patients: Israel 2000-2005. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2011, 30, 375-379.	2.9	20
46	Analysis of undiagnosed tuberculosis-related deaths identified at post-mortem among HIV-infected patients in Russia: a descriptive study. <i>BMC Infectious Diseases</i> , 2011, 11, 276.	2.9	6
47	Mechanistically Distinct Nonribosomal Peptide Synthetases Assemble the Structurally Related Antibiotics Viomycin and Capreomycin. <i>ChemBioChem</i> , 2011, 12, 1859-1867.	2.6	6
48	Streptomycin Susceptibility and MDR-TB: Can We Refine the Definition of XDR-TB?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 278-278.	5.6	0
49	The Positive Predictive Value of T-Spot.TB and Tuberculin Skin Test in Patients with Silicosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 277-278.	5.6	1
50	Treatment of tuberculosis: update 2010. <i>European Respiratory Journal</i> , 2011, 37, 441-462.	6.7	92
51	Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2011, 38, 730-733.	6.7	47
52	Pyrazinamide May Improve Fluoroquinolone-Based Treatment of Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5465-5475.	3.2	48
53	Frequency of adverse reactions to first- and second-line anti-tuberculosis chemotherapy in a Korean cohort. <i>International Journal of Tuberculosis and Lung Disease</i> , 2012, 16, 961-966.	1.2	48
55	Acquired Resistance to Second-Line Drugs Among Persons With Tuberculosis in the United States. <i>Clinical Infectious Diseases</i> , 2012, 55, 1600-1607.	5.8	23
56	Risk factors associated with kanamycin-resistant tuberculosis in a Beijing tuberculosis referral hospital. <i>Journal of Medical Microbiology</i> , 2012, 61, 960-967.	1.8	3

#	ARTICLE	IF	CITATIONS
57	Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India. <i>European Respiratory Journal</i> , 2012, 39, 956-962.	6.7	60
58	Multidrug and extensively drug-resistant tuberculosis in Lisbon and Vale do Tejo, Portugal, from 2008 to 2010. <i>International Journal of Mycobacteriology</i> , 2012, 1, 131-136.	0.6	9
59	TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged?. <i>European Respiratory Journal</i> , 2012, 39, 619-625.	6.7	74
60	Mutations in the <i>rpoB</i> Gene and Phenotypic Resistance to Amikacin and Capreomycin in <i>Mycobacterium tuberculosis</i> . <i>Microbial Drug Resistance</i> , 2012, 18, 193-197.	2.0	60
61	Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. <i>European Respiratory Journal</i> , 2012, 40, 1430-1442.	6.7	346
62	Tbnet – Collaborative research on tuberculosis in Europe. <i>European Journal of Microbiology and Immunology</i> , 2012, 2, 264-274.	2.8	15
63	Trisubstituted Imidazoles as <i>Mycobacterium tuberculosis</i> Glutamine Synthetase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 2894-2898.	6.4	63
64	Microwave-assisted synthesis of small molecules targeting the infectious diseases tuberculosis, HIV/AIDS, malaria and hepatitis C. <i>Organic and Biomolecular Chemistry</i> , 2012, 10, 2713.	2.8	49
65	Microevolution of extensively drug-resistant tuberculosis in Russia. <i>Genome Research</i> , 2012, 22, 735-745.	5.5	173
66	<i>Mycobacterium tuberculosis</i> mutants with multidrug resistance: History of origin, genetic and molecular mechanisms of resistance, and emerging challenges. <i>Russian Journal of Genetics</i> , 2012, 48, 1-14.	0.6	17
67	Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2013, 41, 1393-1400.	6.7	307
68	Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: Update 2012. <i>Respirology</i> , 2013, 18, 8-21.	2.3	54
69	Predictors of treatment outcome in multidrug-resistant tuberculosis in Portugal: Table 1. <i>European Respiratory Journal</i> , 2013, 42, 1747-1749.	6.7	12
70	Do we need a new Fleming Époque: The nightmare of drug-resistant tuberculosis. <i>International Journal of Mycobacteriology</i> , 2013, 2, 123-125.	0.6	9
71	Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. <i>European Respiratory Journal</i> , 2013, 42, 169-179.	6.7	226
73	Comparative roles of moxifloxacin and levofloxacin in the treatment of pulmonary multidrug-resistant tuberculosis: a retrospective study. <i>International Journal of Antimicrobial Agents</i> , 2013, 42, 36-41.	2.5	25
74	Management of drug-resistant tuberculosis. <i>Current Respiratory Care Reports</i> , 2013, 2, 208-217.	0.6	9
75	Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. <i>European Respiratory Journal</i> , 2013, 42, 156-168.	6.7	346

#	ARTICLE	IF	CITATIONS
76	First- and Second-Line Drugs and Drug Resistance. , 0, , .		22
77	Drug-Associated Adverse Events and Their Relationship with Outcomes in Patients Receiving Treatment for Extensively Drug-Resistant Tuberculosis in South Africa. PLoS ONE, 2013, 8, e63057.	2.5	71
78	Illness perception in tuberculosis by implementation of the Brief Illness Perception Questionnaire – a TBNET study. SpringerPlus, 2014, 3, 664.	1.2	9
79	De-novo XDR tuberculosis spine in a 3-year-old girl. Journal of Global Infectious Diseases, 2014, 6, 44.	0.5	0
80	A case of subcutaneous phaeohyphomycosis in a diabetic patient: A cryptic entity. Journal of Global Infectious Diseases, 2014, 6, 45.	0.5	3
81	Linezolid in the treatment of extensively drug-resistant tuberculosis. Infection, 2014, 42, 705-711.	4.7	41
82	Primary Capreomycin Resistance Is Common and Associated With Early Mortality in Patients With Extensively Drug-Resistant Tuberculosis in KwaZulu-Natal, South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, 536-543.	2.1	12
83	High Frequency of Resistance, Lack of Clinical Benefit, and Poor Outcomes in Capreomycin Treated South African Patients with Extensively Drug-Resistant Tuberculosis. PLoS ONE, 2015, 10, e0123655.	2.5	19
84	Multidrug resistant tuberculosis treatment in India. Drug Discoveries and Therapeutics, 2015, 9, 156-164.	1.5	3
85	Multidrug-resistant tuberculosis in New South Wales, Australia, 1999–2010: a case series report. International Journal of Tuberculosis and Lung Disease, 2015, 19, 850-856.	1.2	2
86	Clinical research in the treatment of tuberculosis: current status and future prospects. International Journal of Tuberculosis and Lung Disease, 2015, 19, 1417-1427.	1.2	6
87	A close-up on the epidemiology and transmission of multidrug-resistant tuberculosis in Poland. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 41-53.	2.9	11
88	Fragment Discovery for the Design of Nitrogen Heterocycles as <i>Mycobacterium tuberculosis</i> Dihydrofolate Reductase Inhibitors. Archiv Der Pharmazie, 2016, 349, 602-613.	4.1	12
89	Correlating rrs and eis promoter mutations in clinical isolates of <i>Mycobacterium tuberculosis</i> with phenotypic susceptibility levels to the second-line injectables. International Journal of Mycobacteriology, 2016, 5, 1-6.	0.6	42
91	Tuberculosis: A basic discourse. Apollo Medicine, 2016, 13, 86-90.	0.0	2
92	Status of drug-resistant tuberculosis in China: A systematic review and meta-analysis. American Journal of Infection Control, 2016, 44, 671-676.	2.3	14
93	Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy. Journal of Market Access & Health Policy, 2017, 5, 1283105.	1.5	8
94	Isolation of anti-mycobacterial compounds from <i>Curtisia dentata</i> (Burm.f.) C.A.Sm (Curtisiaceae). BMC Complementary and Alternative Medicine, 2017, 17, 306.	3.7	19

#	ARTICLE	IF	CITATIONS
95	The devil we know: is the use of injectable agents for the treatment of MDR-TB justified?. International Journal of Tuberculosis and Lung Disease, 2017, 21, 1114-1126.	1.2	60
96	Epidemiological trends and outcomes of extensively drug-resistant tuberculosis in Shandong, China. BMC Infectious Diseases, 2017, 17, 555.	2.9	15
97	Molecular Quantum Similarity, Chemical Reactivity and Database Screening of 3D Pharmacophores of the Protein Kinases A, B and G from Mycobacterium tuberculosis. Molecules, 2017, 22, 1027.	3.8	10
98	Validation of the FluoroType <sup>®</sup> MTBDR assay using respiratory and lymph node samples. Tuberculosis, 2018, 113, 76-80.	1.9	6
99	Synthesis and mycobacterial evaluation of 5-substituted-6-acetyl-2-amino-7-methyl-5,8-dihydropyrido[2,3-d]pyrimidin-4(3H)-one derivatives. Archiv Der Pharmazie, 2019, 352, 1900068.		
100	Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres. BMC Infectious Diseases, 2019, 19, 564.	2.9	18
103	Ambulatory management of pre- and extensively drug resistant tuberculosis patients with imipenem delivered through port-a-cath: A mixed methods study on treatment outcomes and challenges. PLoS ONE, 2020, 15, e0234651.	2.5	9
104	Evaluation of drug-resistant tuberculosis treatment outcome in Portugal, 2000-2016. PLoS ONE, 2021, 16, e0250028.	2.5	7
105	Lesion Penetration and Activity Limit the Utility of Second-Line Injectable Agents in Pulmonary Tuberculosis. Antimicrobial Agents and Chemotherapy, 2021, 65, e0050621.	3.2	12
106	Risk Factors for MDR and XDR-TB in a Tertiary Referral Hospital in India. PLoS ONE, 2010, 5, e9527.	2.5	45
107	Tuberculosis - Present Medication and Therapeutic Prospects. Current Medicinal Chemistry, 2020, 27, 630-656.	2.4	2
108	Nano-antimicrobials: A New Paradigm for Combating Mycobacterial Resistance. Current Pharmaceutical Design, 2019, 25, 1554-1579.	1.9	21
109	Design, Synthesis and Antimycobacterial Activity of Some New Pyridazine Derivatives: Bis-pyridazine. Part IV<sup>12-14</sup>. Infectious Disorders - Drug Targets, 2014, 13, 344-351.	0.8	12
110	Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007. Eurosurveillance, 2013, 18, .	7.0	60
111	Validity of Time to Sputum Culture Conversion to Predict Cure in Patients with Multidrug-Resistant Tuberculosis: A Retrospective Single-Center Study. American Journal of Tropical Medicine and Hygiene, 2018, 98, 1629-1636.	1.4	19
112	Treatment of Drug-Resistant Tuberculosis: Review. Turkiye Klinikleri Journal of Medical Sciences, 2012, 32, 788-804.	0.1	3
113	IN - VITRO EVALUATION OF SUSCEPTIBILITY OF M. TUBERCULOSIS TO SECOND LINE OF DRUGS. Journal of Evidence Based Medicine and Healthcare, 2014, 1, 1836-1842.	0.0	0
114	TO STUDY THE PERCEPTION OF PATIENTS ABOUT DURATION OF TREATMENT AND CURABILITY OF TUBERCULOSIS DISEASE TREATED UNDER RNTCP IN KARAD TUBERCULOSIS UNIT. Journal of Evolution of Medical and Dental Sciences, 2015, 4, 3566-3570.	0.1	0

#	ARTICLE	IF	CITATIONS
115	Management of Multidrug-Resistant Tuberculosis Involving the Nervous System. , 2017, , 511-524.		0
116	An Overview on Fluoroquinolone Drugs for the Treatment of Tubercular Infection. International Journal of Biosensors & Bioelectronics, 2017, 2, .	0.2	2
117	A Strategy to Overcome Under-Reporting Issues of Voluntary Medication Error Reporting System, Part II: Changes in Number of Reports by a Counter-error Measureâ€”Computerized Prescriber Order Entry. Biometrics & Biostatistics International Journal, 2017, 5, .	0.2	1
118	Improved early results for patients with extensively drug-resistant tuberculosis and HIV in South Africa. International Journal of Tuberculosis and Lung Disease, 2009, 13, 855-61.	1.2	37
120	Minimizing nephrotoxicity during multidrug-resistant tuberculosis treatment by the stepwise de-escalation of second-line injectables dosing intervals. Clinical Microbiology and Infection, 2022, , .	6.0	0
121	Role of Plant Secondary Metabolites in Metabolic Disorders. , 2022, , 241-280.		2
122	Biosensors for the detection of <i>Mycobacterium tuberculosis</i> : a comprehensive overview. Critical Reviews in Microbiology, 2022, 48, 784-812.	6.1	11
123	Explorative Analysis of Treatment Outcomes of Levofloxacin- and Moxifloxacin-Based Regimens and Outcome Predictors in Ethiopian MDR-TB Patients: A Prospective Observational Cohort Study. Infection and Drug Resistance, 2021, Volume 14, 5473-5489.	2.7	6
125	Efficacy and Safety of Linezolid in the Treatment of Extensively Drug-Resistant Tuberculosis. Japanese Journal of Infectious Diseases, 2011, 64, 509-512.	1.2	15
126	Rapid Diagnosis of XDR and Pre-XDR TB: A Systematic Review of Available Tools. Archivos De Bronconeumologia, 2022, 58, 809-820.	0.8	4
127	A systematic review on extensively drug-resistant tuberculosis from 2009 to 2020: special emphases on treatment outcomes. Revista Espanola De Quimioterapia, 0, , .	1.3	0
128	TUBERCULOSIS WITH MULTIDRUG-RESISTANT AND EXTENSIVELY DRUG-RESISTANT OF MICOBACTERIUM TUBERCULOSIS IN THE RUSSIAN FEDERATION. Avicenna Bulletin, 2018, 20, 314-319.	0.3	3
129	COMPARATIVE ANALYSIS OF MTB STRAINS WITH DIFFERENT TYPES OF DRUG RESISTANCE IN PULMONARY TUBERCULOSIS IN THE KYRGYZ REPUBLIC. Avicenna Bulletin, 2018, 20, 293-298.	0.3	0
130	Global treatment outcomes of extensively drug-resistant tuberculosis in adults: A systematic review and meta-analysis. Journal of Infection, 2023, 87, 177-189.	3.3	5
131	Bedaquiline, Delamanid, Linezolid, Clofazimine, and Capreomycin MIC Distributions for Drug Resistance Mycobacterium tuberculosis in Shanghai, China. Infection and Drug Resistance, 0, Volume 16, 7587-7595.	2.7	0